Skip to main content
Andre Goy on Muck Rack

Andre Goy

Hackensack
As seen in: Nature, Taylor & Francis Online, Agenda (World Economic Forum), Eyewitness News, Becker's Hospital Review, Healio, HemOnc Today, Blood, ONCOLOGY journal, CURE Magazine and
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service Chairman & Chief Physician Officer - John Theurer Cancer Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andre

Contact Andre, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multidisciplinary Team Is ‘Critical’ in Providing CAR T Therapy for Blood Cancers

|
By Andre Goy
| ONCOLOGY journal Verified
During the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition, CancerNetwork® spoke with Andre Goy, MD, about how a multidisciplinary care team is imperative to administering CAR T-cell therapy to patients with hematologic malignancies quickly, and managing any toxicities.
Open in Who Shared Issue with article?

Unmet Needs in Diffuse Large B-Cell Lymphoma

|
By Andre Goy, Andrew Ip
| ONCOLOGY journal Verified
Transcript: Andre H. Goy, MD: We cure a very large fraction of patients with large cell lymphoma, and CAR [chimeric antigen receptor] T-cell therapy now cures a fraction of the patients. In large cell lymphoma, we probably cure close to 40% with anti-CD19 CAR T-cell therapy. So as you mentioned, it is important to refer those patients to this option because nothing else cures them in that setting.
Open in Who Shared Issue with article?

DLBCL: Treatment Considerations in the Second Line

|
By Andre Goy, Andrew Ip
| ONCOLOGY journal Verified
Transcript: Andre H. Goy, MD: I want to go back to wrap up this conversation. In the second-line setting, now that we have multiple drugs approved, when you see a patient—I know we touched a little on this as we discussed every topic—how do you summarize for our audience how to decide what treatment to give to whom? Andrew Ip, MD: If I don’t say it enough, I’ll say it again.
Open in Who Shared Issue with article?
See all 39 licensed articles (106 Total)